Market Cap 39.26M
Revenue (ttm) 4.01M
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -672.57%
Debt to Equity Ratio 0.00
Volume 107,909,102
Avg Vol 6,541,506
Day's Range N/A - N/A
Shares Out 9.26M
Stochastic %K 37%
Beta -0.68
Analysts Strong Sell
Price Target $21.17

Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
BearTamerTrading
BearTamerTrading Jun. 21 at 2:14 AM
$ATPC $BESS $CAST $CRVO $WPRT 🚨 Third-Party Validation 🚨 Out of curiosity, I searched Bear Tamer Trading using independent AI systems and reviewed the results. What stood out wasn’t the praise—it was the consistency. ✅ X reviewed my account and determined there was no violation. Envy and Hate shall never prosper. ✅ Google AI highlighted the transparency of 500+ archived live streams. ✅ Google AI recognized BTT’s accessible pricing model and educational approach. ✅ Google AI acknowledged the value of allowing traders to experience the platform before spending a dollar. The mission has never changed: 🐻 Transparency 🐻 Education 🐻 Community Thank you to everyone who has supported Bear Tamer Trading and helped build what we have today. Prepare. Focus. Execute. Repeat. 📈
1 · Reply
BearTamerTrading
BearTamerTrading Jun. 21 at 12:47 AM
$ATPC $BESS $CAST $CRVO $WPRT What an incredible run we have been on as a community, a trading family that supports and uplifts each other. After all this time if you are screaming scam, I urge to do a quick google, yahoo, or bing search. I can understand the skepticism because there are fakes but I am happy and proud to say we are not ! Let’s keep good times flowing 🔥 Hopefully you guys look us up. https://www.bing.com/search?q=is+bear+tamer+trading+a+scam&form=ANNTH1&refig=6a37289ff5ec4aa79474eb1622e5214c&pc=DCTS
0 · Reply
BearTamerTrading
BearTamerTrading Jun. 21 at 12:47 AM
$ATPC $BESS $CAST $CRVO $WPRT What an incredible run we have been on as a community, a trading family that supports and uplifts each other. After all this time if you are screaming scam, I urge to do a quick google, yahoo, or bing search. I can understand the skepticism because there are fakes but I am happy and proud to say we are not ! Let’s keep good times flowing 🔥 Hopefully you guys look us up. https://www.bing.com/search?q=is+bear+tamer+trading+a+scam&form=ANNTH1&refig=6a37289ff5ec4aa79474eb1622e5214c&pc=DCTS
0 · Reply
JesusIsComingSoon
JesusIsComingSoon Jun. 20 at 9:36 PM
$CRVO People think this is over, I think it's just getting started. And if I'm right, this things going to the BIG B Club.
1 · Reply
pregn4nt
pregn4nt Jun. 20 at 6:16 PM
$CRVO Upcoming milestones: Early Q4 2026 – Preliminary Biomarker Data: CervoMed expects to release important preliminary biomarker and clinical efficacy data for its lead drug candidate, neflamapimod. These findings are considered a critical indicator of the drug's long-term success. ​ Second Half of 2026 – Initiation of Phase 3 Trial: The company is planning to launch its final Phase 3 clinical trial evaluating neflamapimod in patients with Dementia with Lewy Bodies (DLB). ​ End of 2026/Beginning 2027 Focus on Strategic Partnerships: Management's top strategic priority is currently to secure a partnership (e.g., with a larger pharmaceutical company) to co-fund and advance the Phase 3 development program.
0 · Reply
Fettenajs2026
Fettenajs2026 Jun. 20 at 8:29 AM
$CRVO Buy and hold to september/october thank me later
2 · Reply
ROCKETIO
ROCKETIO Jun. 20 at 12:29 AM
$CRVO this stock deserves be delisted.
2 · Reply
Twits4twits
Twits4twits Jun. 20 at 12:12 AM
$CRVO what a fkn abortion this was. Bull shit markets.
1 · Reply
Piterbe
Piterbe Jun. 19 at 7:30 PM
$CRVO ask 4.94 Yahoo Finance 🫣
0 · Reply
Toptradersam
Toptradersam Jun. 19 at 3:13 PM
$CRVO I break down why this stock is on my radar and the key levels I'm watching heading into the next session. 📈 https://www.youtube.com/watch?v=TRjO0OHTtiI
1 · Reply
Latest News on CRVO
CervoMed announces $10.5M private placement

2026-06-10T11:44:51.000Z - 10 days ago

CervoMed announces $10.5M private placement


CervoMed announces $10.5M private placement

2026-06-10T11:41:14.000Z - 10 days ago

CervoMed announces $10.5M private placement


CervoMed Slides: Corporate presentation

Jun 10, 2026, 7:00 AM EDT - 10 days ago

CervoMed Slides: Corporate presentation


CervoMed price target lowered to $9 from $11 at Roth Capital

2026-05-18T21:35:08.000Z - 4 weeks ago

CervoMed price target lowered to $9 from $11 at Roth Capital


CervoMed Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

CervoMed Quarterly report: Q1 2026


CervoMed Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

CervoMed Earnings release: Q1 2026


CervoMed Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

CervoMed Proxy statement: Proxy filing


CervoMed presents neflamapimod MRI data

2026-04-22T14:32:59.000Z - 2 months ago

CervoMed presents neflamapimod MRI data


CervoMed Transcript: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 3 months ago

CervoMed Transcript: The 38th Annual Roth Conference


CervoMed Slides: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 3 months ago

CervoMed Slides: The 38th Annual Roth Conference


CervoMed’s neflamapimod shows efficacy in dementia with DLB

2026-03-19T11:56:17.000Z - 3 months ago

CervoMed’s neflamapimod shows efficacy in dementia with DLB


CervoMed price target lowered to $11 from $19 at Roth Capital

2026-03-17T23:00:26.000Z - 3 months ago

CervoMed price target lowered to $11 from $19 at Roth Capital


CervoMed price target raised to $21 from $15 at Chardan

2026-03-17T22:25:46.000Z - 3 months ago

CervoMed price target raised to $21 from $15 at Chardan


CervoMed Earnings release: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 3 months ago

CervoMed Earnings release: Q4 2025


CervoMed Annual report: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 3 months ago

CervoMed Annual report: Q4 2025


CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024

2026-03-17T11:46:53.000Z - 3 months ago

CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024


CervoMed Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 3 months ago

CervoMed Slides: Corporate presentation


CervoMed completes Phase 1 volunteer study for neflamapimod

2026-03-04T12:41:24.000Z - 3 months ago

CervoMed completes Phase 1 volunteer study for neflamapimod


CervoMed initiated with an Overweight at Cantor Fitzgerald

2025-12-18T11:40:57.000Z - 6 months ago

CervoMed initiated with an Overweight at Cantor Fitzgerald


CervoMed’s neflamapimod shows efficacy in slowing dementia

2025-12-04T22:05:45.000Z - 7 months ago

CervoMed’s neflamapimod shows efficacy in slowing dementia


CervoMed price target lowered to $19 from $20 at Roth Capital

2025-11-10T19:35:22.000Z - 7 months ago

CervoMed price target lowered to $19 from $20 at Roth Capital


CervoMed reports Q3 EPS (84c), consensus (56c)

2025-11-10T12:11:54.000Z - 7 months ago

CervoMed reports Q3 EPS (84c), consensus (56c)


CervoMed Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 8 months ago

CervoMed Earnings release: Q3 2025


CervoMed Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 8 months ago

CervoMed Quarterly report: Q3 2025


CervoMed upgraded to Buy from Neutral at H.C. Wainwright

2025-11-05T11:15:32.000Z - 8 months ago

CervoMed upgraded to Buy from Neutral at H.C. Wainwright


CervoMed Transcript: Emerging Growth Conference

Oct 22, 2025, 11:25 AM EDT - 8 months ago

CervoMed Transcript: Emerging Growth Conference


CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 8 months ago

CervoMed to Present at the Emerging Growth Conference


CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 10 months ago

CervoMed to Participate in Upcoming Investor Conferences


CervoMed Earnings release: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 11 months ago

CervoMed Earnings release: Q2 2025


CervoMed Quarterly report: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 11 months ago

CervoMed Quarterly report: Q2 2025


CervoMed Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 11 months ago

CervoMed Transcript: Status Update


CervoMed Press release: Status Update

Jul 28, 2025, 8:00 AM EDT - 11 months ago

CervoMed Press release: Status Update


CervoMed Slides: Status Update

Jul 28, 2025, 8:00 AM EDT - 11 months ago

CervoMed Slides: Status Update


CervoMed Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation


CervoMed Slides: Corporate Presentation

May 28, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation


CervoMed Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Earnings release: Q1 2025


CervoMed Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Quarterly report: Q1 2025


CervoMed Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

CervoMed Proxy statement: Proxy Filing


CervoMed Slides: Investor Presentation

Apr 5, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation


CervoMed Earnings release: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q4 2024


CervoMed Annual report: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Annual report: Q4 2024


CervoMed Slides: Investor Presentation

Mar 11, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation


CervoMed Slides: Investor Presentation

Jan 31, 2025, 7:00 AM EST - 1 year ago

CervoMed Slides: Investor Presentation


CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals


CervoMed Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 3:00 PM EST - 1 year ago

CervoMed Transcript: Stifel 2024 Healthcare Conference


CervoMed Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Quarterly report: Q3 2024


CervoMed Registration statement: Registration Filing

Oct 3, 2024, 8:00 AM EDT - 1 year ago

CervoMed Registration statement: Registration Filing


CervoMed Quarterly report: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q2 2024


CervoMed Earnings release: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Earnings release: Q2 2024


CervoMed Transcript: Status Update

Jul 23, 2024, 10:00 AM EDT - 2 years ago

CervoMed Transcript: Status Update


CervoMed Slides: Corporate Presentation

Jul 22, 2024, 8:00 AM EDT - 2 years ago

CervoMed Slides: Corporate Presentation


CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in the Emerging Growth Conference


CervoMed Registration statement: Registration Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing


CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Appoint William Elder as Chief Financial Officer


CervoMed Quarterly report: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q1 2024


CervoMed Earnings release: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Earnings release: Q1 2024


CervoMed Registration statement: Registration Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing


CervoMed Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

CervoMed Proxy statement: Proxy Filing


CervoMed Earnings release: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

CervoMed Earnings release: Q4 2023


CervoMed Annual report: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

CervoMed Annual report: Q4 2023


CervoMed to Participate in the BIO CEO and Investor Conference

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference


CervoMed to Participate in the Emerging Growth Conference 67

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67


CervoMed to Participate in the Emerging Growth Conference 66

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66


BearTamerTrading
BearTamerTrading Jun. 21 at 2:14 AM
$ATPC $BESS $CAST $CRVO $WPRT 🚨 Third-Party Validation 🚨 Out of curiosity, I searched Bear Tamer Trading using independent AI systems and reviewed the results. What stood out wasn’t the praise—it was the consistency. ✅ X reviewed my account and determined there was no violation. Envy and Hate shall never prosper. ✅ Google AI highlighted the transparency of 500+ archived live streams. ✅ Google AI recognized BTT’s accessible pricing model and educational approach. ✅ Google AI acknowledged the value of allowing traders to experience the platform before spending a dollar. The mission has never changed: 🐻 Transparency 🐻 Education 🐻 Community Thank you to everyone who has supported Bear Tamer Trading and helped build what we have today. Prepare. Focus. Execute. Repeat. 📈
1 · Reply
BearTamerTrading
BearTamerTrading Jun. 21 at 12:47 AM
$ATPC $BESS $CAST $CRVO $WPRT What an incredible run we have been on as a community, a trading family that supports and uplifts each other. After all this time if you are screaming scam, I urge to do a quick google, yahoo, or bing search. I can understand the skepticism because there are fakes but I am happy and proud to say we are not ! Let’s keep good times flowing 🔥 Hopefully you guys look us up. https://www.bing.com/search?q=is+bear+tamer+trading+a+scam&form=ANNTH1&refig=6a37289ff5ec4aa79474eb1622e5214c&pc=DCTS
0 · Reply
BearTamerTrading
BearTamerTrading Jun. 21 at 12:47 AM
$ATPC $BESS $CAST $CRVO $WPRT What an incredible run we have been on as a community, a trading family that supports and uplifts each other. After all this time if you are screaming scam, I urge to do a quick google, yahoo, or bing search. I can understand the skepticism because there are fakes but I am happy and proud to say we are not ! Let’s keep good times flowing 🔥 Hopefully you guys look us up. https://www.bing.com/search?q=is+bear+tamer+trading+a+scam&form=ANNTH1&refig=6a37289ff5ec4aa79474eb1622e5214c&pc=DCTS
0 · Reply
JesusIsComingSoon
JesusIsComingSoon Jun. 20 at 9:36 PM
$CRVO People think this is over, I think it's just getting started. And if I'm right, this things going to the BIG B Club.
1 · Reply
pregn4nt
pregn4nt Jun. 20 at 6:16 PM
$CRVO Upcoming milestones: Early Q4 2026 – Preliminary Biomarker Data: CervoMed expects to release important preliminary biomarker and clinical efficacy data for its lead drug candidate, neflamapimod. These findings are considered a critical indicator of the drug's long-term success. ​ Second Half of 2026 – Initiation of Phase 3 Trial: The company is planning to launch its final Phase 3 clinical trial evaluating neflamapimod in patients with Dementia with Lewy Bodies (DLB). ​ End of 2026/Beginning 2027 Focus on Strategic Partnerships: Management's top strategic priority is currently to secure a partnership (e.g., with a larger pharmaceutical company) to co-fund and advance the Phase 3 development program.
0 · Reply
Fettenajs2026
Fettenajs2026 Jun. 20 at 8:29 AM
$CRVO Buy and hold to september/october thank me later
2 · Reply
ROCKETIO
ROCKETIO Jun. 20 at 12:29 AM
$CRVO this stock deserves be delisted.
2 · Reply
Twits4twits
Twits4twits Jun. 20 at 12:12 AM
$CRVO what a fkn abortion this was. Bull shit markets.
1 · Reply
Piterbe
Piterbe Jun. 19 at 7:30 PM
$CRVO ask 4.94 Yahoo Finance 🫣
0 · Reply
Toptradersam
Toptradersam Jun. 19 at 3:13 PM
$CRVO I break down why this stock is on my radar and the key levels I'm watching heading into the next session. 📈 https://www.youtube.com/watch?v=TRjO0OHTtiI
1 · Reply
walker7782
walker7782 Jun. 19 at 12:58 PM
$CRVO Starter at $3.99
0 · Reply
BigBuford
BigBuford Jun. 19 at 12:34 PM
$CRVO because more people sold than bought…
2 · Reply
goudaconjo
goudaconjo Jun. 19 at 12:10 PM
$CRVO why did this go down?
3 · Reply
Hdawg1YOLO
Hdawg1YOLO Jun. 19 at 11:46 AM
$ATPC $CRVO $NEOV $OUST $QTRX Signals from earlier this morning
0 · Reply
Hdawg1YOLO
Hdawg1YOLO Jun. 19 at 11:15 AM
🚨 PREMARKET WATCHLIST https://bullish-signals.replit.app **1. $CRVO **Price:** 4.24 **Bullish Score:** 10/10 **2. $ATPC **Price:** 3.88 **Bullish Score:** 10/10 **3. $NEOV **Price:** 2.78 **Bullish Score:** 9/10 **4. $QTRX **Price:** 3.39 **Bullish Score:** 9/10 **5. $OUST **Price:** 46.57 **Bullish Score:** 9/10 **All five offer exceptional momentum, with outsized risk/reward. However, manage risk: parabolic structures can reverse sharply.**
2 · Reply
elbardinnyo
elbardinnyo Jun. 19 at 10:56 AM
$CRVO ask price at 5.5 again on interactive brokers!!!! Something big is on the way
0 · Reply
whiteywhite
whiteywhite Jun. 19 at 7:42 AM
$CRVO why did drop so fast at 12:35 eastern (6/18/26) and yet the volume during that time was not significant? i'm new to day trading and this is crazy to me. any insight appreciated. thanks
1 · Reply
BPler
BPler Jun. 19 at 6:17 AM
$CRVO So what happens if your holding now a bag and see PTs with 20+ but fear it can't even stay above 4: Phase 3 (no external financing) start will bring it 9 to 11 USD probably, if it ia done with dillutive or near term dilution solution. The real kicker (why Insider buy and patent jump-started it even before) Phase 3 with co-fund 19.5 to 21 USD: Management has explicitly stated that their core strategic priority is to secure a major pharmaceutical partner to co-fund and co-commercialize the Phase 3 trial for Dementia with Lewy Bodies (DLB). If they start Phase 3 alongside a major partnership announcement, the consensus fair value shifts to $19.50 to $21.00 (supported by firms like Chardan and the broader S&P Global analyst poll).
1 · Reply
MapNeeds
MapNeeds Jun. 19 at 3:49 AM
Today's tape: 180 breakouts on 25 tickers. 20 more on scan log . 66% Follow-Through (119/180) . FT measures price direction only, not trading profits. Past data ≠ future moves. $CAST — reclaimed premarket 4:14 @ $6.27. Streaming tech, Starlink Business reseller deal. Range L$5.25 - H$16.2 , ~112M shares with FT 🟢 85% (23/27). $CDT — broke fresh premarket 8:32 @ $1.20. Biopharma developer, Sarborg stake fundraising news. Range L$0.68 - H$1.96 , ~249M shares with FT 🟢 76% (16/21). $LNKS — kicked off premarket 4:05 @ $3.51. Industrials microcap, $2.35M Thailand LPW Electronics stake. Range L$2.16 - H$4.98 , ~70M shares with FT 🟡 50% (13/26). $CRVO — popped premarket 7:53 @ $4.87. Neuro biotech, $10M registered direct offering. Range L$3.67 - H$7.81 , ~108M shares with FT 🟢 85% (11/13). $ATPC — lit up premarket 4:22 @ $3.96. Health & wellness, $3M cap. Range L$2.66 - H$6.12 , ~72M shares with FT 🟡 63% (10/16).
0 · Reply
ibaian
ibaian Jun. 19 at 3:44 AM
$CRVO I mentioned this three days ago, I bought many at 3.15
0 · Reply
ibaian
ibaian Jun. 19 at 3:44 AM
$CRVO very true
0 · Reply
ibaian
ibaian Jun. 19 at 3:43 AM
$CRVO Beyond DLB, the company is advancing additional neurological programs, including a Phase 2a study in nonfluent variant primary progressive aphasia (nfvPPA) and a planned Phase 2a ALS trial. Interim biomarker data expected later this year could provide additional insight into the broader potential of neflamapimod across multiple neurodegenerative disorders. For biotechnology investors seeking exposure to neuroscience, NASDAQ: CRVO remains a company closely tied to future clinical execution, regulatory progress, financing developments, and potential partnership opportunities that could support later-stage development efforts.
0 · Reply